SCHEMBL25005507

SCHEMBL25005507

COc1ncc(-c2cc(N3C4CCC3CC4)c3nccn3n2)c(OC)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MDM2 Q00987 12/20 0.38
▸ TP53 P04637 8/20 0.38
▸ MDM4 O15151 2/20 0.38
▸ PPARD Q03181 1/20 0.35
▸ QPCT Q16769 1/20 0.35
▸ QPCTL Q9NXS2 1/20 0.35
▸ MTOR P42345 2/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ SYK P43405 1/20 0.34
▸ PIK3CD O00329 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ EGFR P00533 1/20 0.34
▸ HCK P08631 1/20 0.34
▸ SRC P12931 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ PIK3CB P42338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25005676 0.97 MDM2 (0.36) MDM2TP53MDM4PPARDQPCT
SCHEMBL30224518 0.87 MTOR (0.36) MDM2TP53MDM4PPARDQPCT
SCHEMBL25005978 0.87 MTOR (0.36) MDM2TP53MDM4PPARDQPCT
SCHEMBL25004957 0.87 MTOR (0.36) MDM2TP53MDM4PPARDQPCT
SCHEMBL30224496 0.85 MTOR (0.35) MDM2TP53MDM4PPARDMTOR
SCHEMBL25005578 0.85 MTOR (0.35) MDM2TP53MDM4PPARDMTOR
SCHEMBL30224541 0.85 PPARD (0.34) MDM2MDM4PPARDQPCTQPCTL
SCHEMBL23995187 0.85 PPARD (0.34) MDM2MDM4PPARDQPCTQPCTL
SCHEMBL23992929 0.84 PLAU (0.38) MTORSYKPIK3CDABL1EGFR
SCHEMBL30224149 0.84 PLAU (0.38) MTORSYKPIK3CDABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4143194-A1 CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-03-08 — — EP disclosed
US-20230039553-A1 CD73 COMPOUNDS GILEAD SCIENCES, INC. 2023-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039553-A1 CD73 COMPOUNDS ENTPD5, ENTPD1, NT5E MDM2 2083/4885TP53 85/4885MDM4 2444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback